The Lancet Regional Health–Americas published the study, a randomized clinical trial of the effect of metformin on hospitalization rates among COVID-19 patients, in December 2021. In December 2023, the authors "identified small errors in the statistical analysis primary outcome". At that point, the journal asked the university to investigate.
It was received the final report from McMaster University on 21st April 2025 which stated the hearing committee concluded the author did not breach the University’s research integrity policy. "So a year and 3 months just for them to agree that we weren’t conducting any malfeasance", Edward Mills, corresponding author, said. He said he expects the correction will be published "within the next few weeks".
